Oncology
Refractory or Recurrent Solid Tumor
0
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Refractory or Recurrent Solid Tumor is an early-stage landscape with 0 programs across 4 companies. The most active players are Amgen, SynerGene Therapeutics, Inc., Eisai.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Completed4 · 67%
Suspended1 · 17%
Recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)
Completed·—·Phase 1·NCT00586560·15 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)